BioSpace News Archive

Optinose today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors.

Attralus, Inc. today announced encouraging new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal (PAR) therapeutic being developed for the treatment of systemic amyloidosis.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced new data in oral and poster presentations at the American Society of Hematology annual meeting in Atlanta, Georgia, and on a virtual platform.

Aquestive Therapeutics, Inc. today reported that it has received a written response from FDA to its pre-investigational new drug (pre-IND) meeting submission confirming that the development of AQST-109 for the treatment of anaphylaxis under the 505(b)(2) pathway is acceptable.

X4 Pharmaceuticals, Inc. today highlighted key takeaways from three clinical and scientific posters presented over the weekend at the American Society of Hematology (ASH) Annual Meeting, taking place both virtually and in person in Atlanta, GA from December 11-14, 2021.

Oncternal Therapeutics, Inc. today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in a poster presentation at the American Society of Hematology (ASH) 2021 Annual Meeting.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), today announced that, following a review of the Company’s preclinical and clinical data, study design, and manufacturing process, Greece’s National Organization of Medicines has authorized the expansion of the Company’s Phase IIb trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distress syndrome (ARDS) to sites in the country.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), today reported interim results from its Phase 1/2 PRIME clinical trial of P-BCMA-101 for the treatment of relapsed/refractory multiple myeloma (R/R MM) at the 2021 American Society of Hematology (ASH) Annual Meeting.

People with HIV are at higher risk of developing heart failure than people without HIV, a new study found.

The term, virtual rehabilitation (VR), is used to explain a kind of training wherein patients interact with virtual or augmented environments, presented with the help of technology.